Attached files

file filename
10-K - 10-K - IOVANCE BIOTHERAPEUTICS, INC.iova-20191231x10kab9a30.htm
EX-32.2 - EX-32.2 - IOVANCE BIOTHERAPEUTICS, INC.ex-32d2.htm
EX-32.1 - EX-32.1 - IOVANCE BIOTHERAPEUTICS, INC.ex-32d1.htm
EX-31.2 - EX-31.2 - IOVANCE BIOTHERAPEUTICS, INC.ex-31d2.htm
EX-31.1 - EX-31.1 - IOVANCE BIOTHERAPEUTICS, INC.ex-31d1.htm
EX-21.1 - EX-21.1 - IOVANCE BIOTHERAPEUTICS, INC.ex-21d1.htm
EX-10.11 - EX-10.11 - IOVANCE BIOTHERAPEUTICS, INC.ex-10d11.htm
EX-10.10 - EX-10.10 - IOVANCE BIOTHERAPEUTICS, INC.ex-10d10.htm
EX-10.8 - EX-10.8 - IOVANCE BIOTHERAPEUTICS, INC.ex-10d8.htm
EX-10.7 - EX-10.7 - IOVANCE BIOTHERAPEUTICS, INC.ex-10d7.htm
EX-10.5 - EX-10.5 - IOVANCE BIOTHERAPEUTICS, INC.ex-10d5.htm
EX-10.4 - EX-10.4 - IOVANCE BIOTHERAPEUTICS, INC.ex-10d4.htm
EX-4.3 - EX-4.3 - IOVANCE BIOTHERAPEUTICS, INC.ex-4d3.htm

Exhibit 23.1

 

INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM’S CONSENT

 

We consent to the incorporation by reference in the Registration Statements of Iovance Biotherapeutics, Inc. on Form S-3 (File No. 333-233578), Form S-3 (File No. 333-214073), Form S-3 (File No. 333-212373), Form S-8 (File No. 333-217638), Form S-8 (File No. 333-214567), Form S-8 (File No. 333-205097), and Form S-8 (File No. 333-227242) of our report dated February 25, 2020, with respect to our audits of the consolidated financial statements of Iovance Biotherapeutics, Inc. as of December 31, 2019 and 2018 and for each of the three years in the period ended December 31, 2019 and our report dated February 25, 2020 with respect to our audit of the effectiveness of internal control over financial reporting of Iovance Biotherapeutics, Inc. as of December 31, 2019, which reports are included in this Annual Report on Form 10-K of Iovance Biotherapeutics, Inc. for the year ended December 31, 2019.

 

 

/s/ Marcum LLP

 

 

 

 

 

Marcum LLP

 

 

New York, NY

 

 

February 25, 2020